Clearside Biomedical, Inc. Employee Directory
Biotechnology ResearchGeorgia, United States11-50 Employees
Clearside Biomedical is a biotechnology company focused on delivering therapies to the back of the eye via the suprachoroidal space. Its SCS injection platform, including a proprietary Microinjector, enables an in-office, repeatable, non-surgical procedure to deliver treatments selectively to the macula, retina, or choroid with the aim of preserving or improving vision. The company pursues a pipeline of small molecule candidates for administration through this platform and collaborates with other ophthalmic innovators to apply the technology; its first product, XIPERE, was approved by the U.S. FDA in October 2021 for suprachoroidal use.